SynCore Biotechnology Co (ROCO:4192) Total Current Liabilities: NT$10.07 Mil (As of Dec. 2025)


ROCO:4192 SynCore Biotechnology Co Ltd ROCO:4192
67 GF Score
Price NT$20.50
GF Value NT$47.95
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is SynCore Biotechnology Co Total Current Liabilities?

SynCore Biotechnology Co ROCO:4192 67 Total Current Liabilities is NT$10.07 Mil as of Dec. 2025. GuruFocus rates ROCO:4192 with a GF Score™ of 67/100 and a GF Value™ of NT$47.95 (Possible Value Trap). The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. SynCore Biotechnology Co's total current liabilities for the quarter that ended in Dec. 2025 was NT$10.07

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

SynCore Biotechnology Co Total Current Liabilities Related Terms

SynCore Biotechnology Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for SynCore Biotechnology Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynCore Biotechnology Co Total Current Liabilities Chart

SynCore Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 381.52 186.64 21.23 22.12 10.07

SynCore Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.12 24.45 21.37 14.88 10.07
ROCO:4192
67GF Score
SynCore Biotechnology Co Ltd ROCO:4192
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynCore Biotechnology Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

SynCore Biotechnology Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.519+2.097
+Other Current Liabilities+Current Deferred Liabilities
=1.458+0
=10.07

SynCore Biotechnology Co's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.519+2.097
+Other Current Liabilities+Current Deferred Liabilities
=1.458+0
=10.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$10.07 Mil mean?
SynCore Biotechnology Co (ROCO:4192) has a Total Current Liabilities of NT$10.07 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for SynCore Biotechnology Co and its competitors.
Is SynCore Biotechnology Co's Total Current Liabilities too high?
SynCore Biotechnology Co's current Total Current Liabilities is NT$10.07 Mil. Overall, SynCore Biotechnology Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's Total Current Liabilities compare to VRTX and REGN?
SynCore Biotechnology Co's Total Current Liabilities of NT$10.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for SynCore Biotechnology Co and its competitors. SynCore Biotechnology Co's current Total Current Liabilities is NT$10.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.95, compared to a current price of NT$20.50 — trading 57.2% below its estimated fair value. The current Total Current Liabilities is NT$10.07 Mil. SynCore Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current Total Current Liabilities is NT$10.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?

Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued. The current stock price of NT$20.50 is trading 57.2% below its estimated GF Value™ of NT$47.95. GuruFocus considers SynCore Biotechnology Co to be Possible Value Trap.

Key valuation signals for ROCO:4192:

  • Total Current Liabilities: NT$10.07 Mil
  • GF Value™: NT$47.95 vs. price of NT$20.50 (57.2% below fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SynCore Biotechnology Co Business Description

Address No. 84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
67GF Score

Get the complete analysis for ROCO:4192

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.50
Price
NT$47.95
GF Value